Theralizumab

DB15717InvestigationalProtein Based Therapies

Theralizumab is a humanized anti-CD28 monoclonal antibody designed for treating autoimmune diseases and cancer. After the first human trial, it was withdrawn due to severe toxicity (likely due to lymphopenia...

Mechanism: Pharmacologically active on T-cell-specific surface glycoprotein CD28
Curator reviewed
Also known as: CD28-SuperMAB
Code names: TAB-08 · TGN-1412

Resolves to

Compound

UNIIPOO0DOD3ASCAS906068-56-2

Targets

P10747CD28

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Theralizumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account